Icodec: A Novel Once-Weekly Basal Insulin for Diabetes Management
Annals of Pharmacotherapy · 2025-06 · 59 (6) · 554-569
DOI: 10.1177/10600280241287790 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 18.10.2024. Verfasst von Jennifer Goldman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Insulin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: novo nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To evaluate the efficacy, safety, and clinical implications of insulin icodec, a novel once-weekly basal insulin for the treatment of type 1 diabetes (T1D) and type 2 diabetes (T2D), with an emphasis on its advantages and challenges in comparison with existing daily basal insulins. Data Sources: A literature search was performed using PubMed, Google Scholar, Embase, and ClinicalTrials.gov up to August 26, 2024, using the search terms icodec and ONWARDS trial . Studies involving patients living with T1D or T2D on once-weekly insulin icodec compared with once-daily insulins glargine U100, glargine U300, and degludec were considered for this review. Study Selection and Data Extraction: Relevant English-language studies and those conducted in humans were considered. Data Synthesis: Insulin icodec offers reduced dosing frequency and potentially superior glycemic management with a safety profile comparable to existing basal insulins. Relevance to Patient Care and Clinical Practice: Insulin icodec once-weekly dosing could significantly improve convenience and efficacy over daily basal insulins, representing a significant innovation in insulin therapy.
Conclusions
Insulin icodec emerges as a promising option for diabetes management, potentially improving treatment adherence and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.
- Texas Diabetes Institute, University Health System; University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
- Endocrinology & Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA.
ORCID-Profile: Jennifer Goldman, Diana Isaacs
Förderung
- novo nordisk
Zitieren
APA
Goldman, J., Triplitt, C., & Isaacs, D. (2025). Icodec: A Novel Once-Weekly Basal Insulin for Diabetes Management. Annals of Pharmacotherapy, 59(6), 554-569. https://doi.org/10.1177/10600280241287790
Vancouver
Goldman J, Triplitt C, Isaacs D. Icodec: A Novel Once-Weekly Basal Insulin for Diabetes Management. Annals of Pharmacotherapy. 2025;59(6):554-569. doi:10.1177/10600280241287790
BibTeX
@article{Goldman2025,
author = {Goldman, Jennifer and Triplitt, Curtis and Isaacs, Diana},
title = {Icodec: A Novel Once-Weekly Basal Insulin for Diabetes Management},
journal = {Annals of Pharmacotherapy},
year = {2025},
volume = {59},
number = {6},
pages = {554--569},
doi = {10.1177/10600280241287790}
}
EUVIMED